Enhanced active agents
US10363318B2 · kind B2 · utility
3Cited by
54References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 16, 2018 |
| Grant date | Jul 30, 2019 |
| Priority date | — |
| Expiry date | Nov 16, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The teachings provide active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Methods of making and using the systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.